ArticleCureus2026
Impact of Intravitreal Ranibizumab on Retinopathy of Prematurity: A Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The purpose of this study was to evaluate the impact of intravitreal ranibizumab (IVR) introduction on treatment patterns for retinopathy of prematurity (ROP) and the incidence of severe complications, including retinal detachment (RD), in a real-world setting. Methods We retrospectively analyzed 785 infants born at ≤1800 g or ≤34 weeks of gestation between January 2016 and December 2022 at two tertiary hospitals in Japan. IVR (0.2 mg/0.02 mL) was introduced in August 2020 at Tohoku University Hospital and in December 2019 at Miyagi Children's Hospital. Infants meeting Early Treatment for Retinopathy of Prematurity (ETROP) criteria received either retinal photocoagulation (RPC), IVR, or both, depending on the treatment era. Severe cases with RD (stage 4A or higher) were managed with scleral buckling or vitreous surgery as needed. Results Of the 472 infants treated prior to IVR introduction, 41.3% were extremely low birth weight (ELBW), comparable to 41.5% among the 291 infants treated after IVR introduction. The proportion undergoing RPC significantly decreased from 9.7% to 5.4% following IVR availability (p=0.03). Notably, the incidence of RD dropped from 2.1% to 0% after IVR introduction (p=0.01), despite no significant change in ELBW distribution. Conclusion The introduction of IVR has markedly shifted ROP treatment paradigms, reducing reliance on RPC and completely eliminating RD in our cohort. IVR offers a targeted, less destructive therapeutic alternative, potentially preserving retinal architecture and improving long-term visual outcomes. While these findings are encouraging, prospective studies are needed to further assess the safety and efficacy of IVR in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.